FDA Advisory Committees Vote to Dismiss Clozapine REMS, Citing Barriers to Access
FDA advisory committees voted 14 to 1 to dismiss the clozapine REMS, deeming the monitoring requirements unnecessary and a barrier to patient access.
Atypical Antipsychotics in Dementia: Balancing Benefits and Risks in BPSD Management
Behavioral and Psychological Symptoms of Dementia (BPSD) affect nearly all dementia patients, increasing hospitalization, neglect, and mortality risks.
© Copyright 2025. All Rights Reserved by MedPath